PL2244722T3 - Leczenie zakażeń drobnoustrojami - Google Patents

Leczenie zakażeń drobnoustrojami

Info

Publication number
PL2244722T3
PL2244722T3 PL09705327T PL09705327T PL2244722T3 PL 2244722 T3 PL2244722 T3 PL 2244722T3 PL 09705327 T PL09705327 T PL 09705327T PL 09705327 T PL09705327 T PL 09705327T PL 2244722 T3 PL2244722 T3 PL 2244722T3
Authority
PL
Poland
Prior art keywords
treatment
microbial infections
infections
microbial
Prior art date
Application number
PL09705327T
Other languages
English (en)
Inventor
Timothy Foster
Judy Higgins
Elisabet Josefsson
Joan Geoghegan
Andrej Tarkowski
Original Assignee
The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40512496&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2244722(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0801768.3A external-priority patent/GB0801768D0/en
Application filed by The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin filed Critical The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin
Publication of PL2244722T3 publication Critical patent/PL2244722T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL09705327T 2008-01-31 2009-01-29 Leczenie zakażeń drobnoustrojami PL2244722T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IE20080070 2008-01-31
GBGB0801768.3A GB0801768D0 (en) 2008-01-31 2008-01-31 Treatment of microbial infections
EP09705327.6A EP2244722B1 (en) 2008-01-31 2009-01-29 Treatment of microbial infections

Publications (1)

Publication Number Publication Date
PL2244722T3 true PL2244722T3 (pl) 2017-04-28

Family

ID=40512496

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09705327T PL2244722T3 (pl) 2008-01-31 2009-01-29 Leczenie zakażeń drobnoustrojami

Country Status (22)

Country Link
US (3) US20110150918A1 (pl)
EP (2) EP2244722B1 (pl)
JP (1) JP5709527B2 (pl)
KR (1) KR101739048B1 (pl)
CN (1) CN101983067B (pl)
AU (1) AU2009209598B2 (pl)
BR (1) BRPI0906997A2 (pl)
CA (1) CA2713241C (pl)
CY (1) CY1118153T1 (pl)
DK (1) DK2244722T3 (pl)
EA (1) EA019516B1 (pl)
ES (2) ES2960604T3 (pl)
HR (1) HRP20161305T1 (pl)
HU (1) HUE031614T2 (pl)
LT (1) LT2244722T (pl)
MX (1) MX2010008423A (pl)
PL (1) PL2244722T3 (pl)
PT (1) PT2244722T (pl)
SG (1) SG188102A1 (pl)
SI (1) SI2244722T1 (pl)
WO (1) WO2009095453A1 (pl)
ZA (1) ZA201005798B (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007221321B2 (en) * 2006-02-22 2012-06-28 The Texas A & M University System Antibodies recognizing a highly expressed putative antigen of CA-MRSA and methods of use
PL2244722T3 (pl) 2008-01-31 2017-04-28 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin Leczenie zakażeń drobnoustrojami
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
BR112012000953A8 (pt) 2009-07-15 2017-12-26 Aimm Therapeutics Bv anticorpos de ligação a bactérias gram-positivas, sequência de ácido nucleico,seus usos e seu método de produção, células isolada ou produtora de anticorpo isolado ou recombinante, composições, e método de isolamento de bactérias
EP2453915B1 (en) 2009-07-16 2017-04-19 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Treatment of infections
GB0913680D0 (en) * 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
EP2488547B1 (en) 2009-10-15 2017-12-06 University Court of the University of Edinburgh Staphylococcal antigens
CN101843899B (zh) * 2010-05-24 2012-11-07 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌（mrsa）重组多亚单位基因工程疫苗及其制备方法
EP2614074A1 (en) 2010-09-09 2013-07-17 The University of Chicago Methods and compositions involving protective staphylococcal antigens
WO2013159021A1 (en) * 2012-04-20 2013-10-24 The Texas A&M University System Engineered collagen binding mscramm with enhanced affinity for collagen
CN104968797B (zh) * 2012-11-06 2018-11-30 米迪缪尼有限公司 金黄色葡萄球菌表面决定簇的抗体
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP3229833A1 (en) * 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Method of treatment
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
GB201802339D0 (en) * 2018-02-13 2018-03-28 Glaxosmithkline Biologicals Sa Immunogenic composition
ES2832881T3 (es) * 2018-04-24 2021-06-11 Fibriant B V Variantes de fibrinógeno gamma prima para su uso en el tratamiento de una infección
IL324411A (en) 2023-05-05 2026-01-01 Sanofi Pasteur Inc Preparations for use in the treatment of acne

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008341A (en) * 1994-08-22 1999-12-28 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin S. aureus fibrinogen binding protein gene
EP1173466A4 (en) * 1999-04-28 2002-10-16 Trinity College Dublin METHOD FOR AVOIDING THE BONDING OF LEUKOCYTES TO FIBRINOGENS
CA2351018A1 (en) * 2001-07-09 2003-01-09 Universite De Sherbrooke Dna vaccine against staphylococcus aureus
US7771731B2 (en) 2004-05-21 2010-08-10 Wyeth Llc Altered fibronectin-binding protein of Staphylococcus aureus
PL2244722T3 (pl) 2008-01-31 2017-04-28 The Provost, Fellows, Foundation Scholars, & The Other Members Of Board, Of The College Of The Holy & Undiv. Trinity Of Queen Elizabeth Near Dublin Leczenie zakażeń drobnoustrojami

Also Published As

Publication number Publication date
ZA201005798B (en) 2013-01-30
EA201001212A1 (ru) 2011-02-28
CY1118153T1 (el) 2017-06-28
US20150232518A1 (en) 2015-08-20
CN101983067A (zh) 2011-03-02
EP3117832B1 (en) 2023-09-27
JP2011510952A (ja) 2011-04-07
US11512118B2 (en) 2022-11-29
SI2244722T1 (sl) 2017-01-31
HUE031614T2 (en) 2017-07-28
US20110150918A1 (en) 2011-06-23
MX2010008423A (es) 2010-09-22
CA2713241C (en) 2022-10-04
BRPI0906997A2 (pt) 2015-07-07
KR20110000624A (ko) 2011-01-04
HRP20161305T1 (hr) 2017-01-27
EP3117832A1 (en) 2017-01-18
EA201001212A8 (ru) 2014-03-31
EA019516B1 (ru) 2014-04-30
EP2244722A1 (en) 2010-11-03
US9637525B2 (en) 2017-05-02
LT2244722T (lt) 2016-10-25
AU2009209598B2 (en) 2012-07-26
KR101739048B1 (ko) 2017-05-23
CN101983067B (zh) 2017-07-11
EP3117832C0 (en) 2023-09-27
AU2009209598A1 (en) 2009-08-06
US20170202943A1 (en) 2017-07-20
EP2244722B1 (en) 2016-07-27
ES2599953T3 (es) 2017-02-06
JP5709527B2 (ja) 2015-04-30
ES2960604T3 (es) 2024-03-05
SG188102A1 (en) 2013-03-28
DK2244722T3 (en) 2016-11-14
PT2244722T (pt) 2016-11-04
WO2009095453A1 (en) 2009-08-06
CA2713241A1 (en) 2009-08-06

Similar Documents

Publication Publication Date Title
ZA201005798B (en) Treatment of microbial infections
IL208354A0 (en) Methods of treatment
PL2326287T3 (pl) Modułowe urządzenie rozprzestrzeniające do leczenia protetycznych zakażeń stawów
ZA200906126B (en) Use of IL-23 antigonists for treatment of infection
GB0818074D0 (en) Treatment of biofilms
GB0802116D0 (en) Treatment
PL2696890T3 (pl) Leczenie infekcji drobnoustrojowych
EP2257569A4 (en) METHOD OF TREATMENT USING ANTIMICROBIAL COMPOSITION
DK2473482T3 (en) Methods of treating orthomyxoviral infections
ZA201100616B (en) Treatment of antibiotic-resistant bacteria infection
GB0811992D0 (en) Treatment
PT2424559T (pt) Métodos de tratamento de infeções bacterianas utilizando oritavancina
GB0513096D0 (en) Treatment of microbial infections
EP2417258A4 (en) BACTERIOPHAGE COMPOSITIONS FOR THE TREATMENT OF BACTERIAL INFECTIONS
ZA201204249B (en) Treatment of microbial infections
EP2164494A4 (en) Methods of Treatment
GB0723100D0 (en) Treatment of HFnEF
PH12012500528A1 (en) Compositions and methods for treating bacterial infections using caftaroline
ZA201100468B (en) The treatment of helminthic infections
GB0805912D0 (en) Treatment
GB0801768D0 (en) Treatment of microbial infections
GB0807781D0 (en) Treatment of bacterial infection
GB0711704D0 (en) Treatment of staphylococcal infections
AU2009900969A0 (en) Treatment of infection
GB0814216D0 (en) Compounds for the treatment of flaviviral infections